Eisai's eribulin misses the capecitabine mark in second-line breast cancer
This article was originally published in Scrip
After an initial 3.3% drop, shares in Eisai closed down by 1.0% in Tokyo on 10 July as the company disclosed that Halaven (eribulin) missed both primary survival endpoints in a comparative Phase III trial as a second-line therapy for advanced breast cancer.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.